The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
Abstract
An outbreak of 2019‐nCoV infection has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID‐2019. In addition to the recommended antiviral drugs, such as interferon‐ɑ, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA‐dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug–drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID‐2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2020) · doi:10.1101/2020.03.17.20037432 · Cited by 852 · cited 6×
“Data obtained from influenza treatment and proof-of-concept clinical trial in EVD aids the determination of dose regimen in clinical trials or experimental use of the drug in COVID-19.”
BackgroundInfluential
Cited by
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.683296 · Cited by 849
Role of favipiravir in the treatment of COVID-19
Joshi, S., Parkar, J., Ansari, A., Vora, A., Talwar, D., Tiwaskar, M., Patil, S., & Barkate, H. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.10.069 · Cited by 462
COVID-19: Drug Targets and Potential Treatments
Gil, C., Ginex, T., Maestro, I., Nozal, V., Barrado-Gil, L., Cuesta-Geijo, M. Á., Urquiza, J., Ramírez, D., Alonso, C., Campillo, N. E., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00606 · Cited by 445
Antiviral treatment of COVID-19
ŞİMŞEK YAVUZ, S., & ÜNAL, S. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-145 · Cited by 367
Kaptein, S. J. F., Jacobs, S., Langendries, L., Seldeslachts, L., ter Horst, S., Liesenborghs, L., Hens, B., Vergote, V., Heylen, E., Barthelemy, K., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014441117 · Cited by 269
Metadata
- Authors
- Du, Y., & Chen, X.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2020-04-21
- Volume
- 108
- Issue
- 2
- Pages
- 242-247
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W3015016176
- Cited by
- 418
- References
- 3
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection. https://app.cochat.ai/papers/10.1002/cpt.1844
- The paper
- Du, Y., & Chen, X. (2020). Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.1844
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
